NovaBay Pharmaceuticals, Inc. (NBY): Price and Financial Metrics
GET POWR RATINGS... FREE!
NBY POWR Grades
- Value is the dimension where NBY ranks best; there it ranks ahead of 86.46% of US stocks.
- NBY's strongest trending metric is Value; it's been moving up over the last 33 days.
- NBY ranks lowest in Momentum; there it ranks in the 4th percentile.
NBY Stock Summary
- NBY has a market capitalization of $4,599,318 -- more than approximately only 0.77% of US stocks.
- With a year-over-year growth in debt of 1,001.02%, NOVABAY PHARMACEUTICALS INC's debt growth rate surpasses 97.91% of about US stocks.
- In terms of volatility of its share price, NBY is more volatile than 99.07% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to NOVABAY PHARMACEUTICALS INC, a group of peers worth examining would be GROW, EBF, IZEA, ZUMZ, and DTEA.
- Visit NBY's SEC page to see the company's official filings. To visit the company's web site, go to www.novabay.com.
NBY Valuation Summary
- In comparison to the median Healthcare stock, NBY's price/sales ratio is 80.95% lower, now standing at 0.4.
- NBY's price/sales ratio has moved down 16.7 over the prior 186 months.
Below are key valuation metrics over time for NBY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NBY | 2023-01-30 | 0.4 | 0.3 | -0.5 | -1.1 |
| NBY | 2023-01-27 | 0.4 | 0.3 | -0.5 | -1.0 |
| NBY | 2023-01-26 | 0.3 | 0.3 | -0.4 | -0.8 |
| NBY | 2023-01-25 | 0.3 | 0.3 | -0.4 | -0.8 |
| NBY | 2023-01-24 | 0.3 | 0.3 | -0.5 | -0.9 |
| NBY | 2023-01-23 | 0.3 | 0.3 | -0.5 | -0.9 |
NBY Growth Metrics
- The 2 year cash and equivalents growth rate now stands at -1.17%.
- Its 5 year net income to common stockholders growth rate is now at 34.8%.
- Its 5 year cash and equivalents growth rate is now at -22.85%.
The table below shows NBY's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 12.141 | -9.763 | -8.952 |
| 2022-06-30 | 10.155 | -9.542 | -5.448 |
| 2022-03-31 | 9.243 | -9.83 | -5.152 |
| 2021-12-31 | 8.421 | -9.192 | -6.559 |
| 2021-09-30 | 7.668 | -6.319 | -7.42 |
| 2021-06-30 | 7.998 | -6.221 | -8.352 |
NBY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NBY has a Quality Grade of C, ranking ahead of 44.35% of graded US stocks.
- NBY's asset turnover comes in at 0.533 -- ranking 79th of 680 Pharmaceutical Products stocks.
- AMGN, AMRN, and UTHR are the stocks whose asset turnover ratios are most correlated with NBY.
The table below shows NBY's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.533 | 0.698 | -7.529 |
| 2021-03-31 | 0.660 | 0.610 | -9.044 |
| 2020-12-31 | 0.722 | 0.600 | -7.838 |
| 2020-09-30 | 0.764 | 0.615 | -6.542 |
| 2020-06-30 | 0.757 | 0.607 | -3.607 |
| 2020-03-31 | 0.620 | 0.717 | -1.768 |
NBY Stock Price Chart Interactive Chart >
NBY Price/Volume Stats
| Current price | $2.47 | 52-week high | $12.96 |
| Prev. close | $2.48 | 52-week low | $1.24 |
| Day low | $2.34 | Volume | 39,400 |
| Day high | $2.58 | Avg. volume | 73,605 |
| 50-day MA | $1.98 | Dividend yield | N/A |
| 200-day MA | $5.60 | Market Cap | 4.63M |
NovaBay Pharmaceuticals, Inc. (NBY) Company Bio
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products for the eye care market in the United States. The company was founded in 2000 and is based in Emeryville, California.
Latest NBY News From Around the Web
Below are the latest news stories about NOVABAY PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NBY as an investment opportunity.
PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care MarketNASHVILLE, Tenn. & EMERYVILLE, Calif., January 17, 2023--PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid. |
Can you now get a good deal on NovaBay Pharmaceuticals Inc.’s shares?In Friday’s session, NovaBay Pharmaceuticals Inc. (AMEX:NBY) marked $1.95 per share, up from $1.39 in the previous session. While NovaBay Pharmaceuticals Inc. has overperformed by 40.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NBY fell by -85.71%, with highs and lows ranging from $14.97 to […] |
NBY, RSLS and FORA among healthcare moversGainers: Palisade Bio PALI +65%.Silo Pharma (SILO) +57%.F-star Therapeutics FSTX +42%.NovaBay Pharmaceuticals (NBY) +31%.Kala Pharmaceuticals KALA +29%.Losers: Hoth… |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! |
NovaBay Pharmaceuticals Announces the Launch of DERMAdoctor’s TikTok Store in China and Expands Online Marketing in the U.S. and ChinaNovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the expansion of its lifestyle promotional video campaigns on TikTok and its Chinese cou |
NBY Price Returns
| 1-mo | 5.11% |
| 3-mo | -30.13% |
| 6-mo | -74.88% |
| 1-year | -77.96% |
| 3-year | -87.87% |
| 5-year | -98.05% |
| YTD | 26.67% |
| 2022 | -85.21% |
| 2021 | -45.97% |
| 2020 | 8.91% |
| 2019 | -16.88% |
| 2018 | -80.00% |
Continue Researching NBY
Want to see what other sources are saying about NovaBay Pharmaceuticals Inc's financials and stock price? Try the links below:NovaBay Pharmaceuticals Inc (NBY) Stock Price | Nasdaq
NovaBay Pharmaceuticals Inc (NBY) Stock Quote, History and News - Yahoo Finance
NovaBay Pharmaceuticals Inc (NBY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...